Background
==========

The large variability among individuals in drug efficacy is a major challenge in current clinical practice, drug development, and drug regulation \[[@b1-medscimonit-21-3769]\]. It has been suggested that genetic background may be responsible for the variation in response to therapy, and mounting evidence demonstrates that an individual's genetic makeup accounts for an estimated 20\~95% of variability in drug disposition and effects \[[@b2-medscimonit-21-3769],[@b3-medscimonit-21-3769]\]. Pharmacogenetics and pharmacogenomics elucidated the inherited nature of individual variation in drug response, with the goal of optimizing efficacy and safety through better understanding of human genetic variability and its influence on drug response, leading to personalized medicine \[[@b4-medscimonit-21-3769],[@b5-medscimonit-21-3769]\].

The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB: *<http://www.pharmgkb.org>*) is a publicly available Web-based knowledge base created to aid researchers in understanding how genetic variation among individuals contributes to differences in reactions to drugs \[[@b6-medscimonit-21-3769]\]. This information is presented in the form of Very Important Pharmacogene (VIP) summaries, pathway diagrams, and curated literature \[[@b7-medscimonit-21-3769]\]. The PharmGKB currently contains information for more than 3000 drugs, 3000 diseases, and 26 000 genes with genotyped variants \[[@b8-medscimonit-21-3769]\]. In total, it consists of 126 VIP variants that occur in 44 different genes and variously code for cytochrome P450 oxidases, drug targets, drug receptors, and drug transporters. The relationship between these VIP variants and their effect on drug-related toxicity as well as therapeutic benefit have been studied extensively \[[@b9-medscimonit-21-3769]\].

Pharmacogenomic research in ethnic populations has great significance for the achievement of personalized drug treatment and development of new drugs. However, we have not found any pharmacogenomics information regarding minority groups, such as the Miao ethnic groups in southwest China. The Miao is an ethnic group mainly distributed in the southwest of China; they mostly live in Guizhou, Yunnan, and Sichuan provinces. It is one of China's largest ethnic groups, with a long history, distinct culture, and fine traditions. According to a 2000 census, the Miao have an approximate population of 9.6 million.

In the present study, we aimed to identify the allele frequencies of VIP variants in the Miao and to determine the difference in allele frequencies between the Miao and 12 other populations. Our goals were to identify differences and determine their extent and provide a theoretical basis for safer drug administration and better therapeutic treatment in the Miao population. The results of our study will extend our understanding of ethnic diversity and pharmacogenomics, and help clinicians triage patients for better individualized treatments.

Material and Methods
====================

Study participants
------------------

We randomly recruited 98 unrelated, healthy Miao subjects from Guizhou province of China. The subjects selected were judged to be of good health and had exclusively Miao ancestry for at least the last 3 generations. We selected 96 unrelated Chinese Han individuals from Lantian county in Xi'an, Shaanxi province as one of our control groups. All subjects were healthy in terms of their medical history and physical examination. An explanation about the purpose and experimental procedures of the study were given to all individuals. Written informed consent was obtained from all subjects prior to sample donation, and the study protocol was performed in accordance with the Declaration of Helsinki and approved by the Clinical Research Ethics of Northwest University for Approval of Research Involving Human Subjects.

Variant selection and genotyping
--------------------------------

We selected genetic variants from published polymorphisms associated with VIP variants from the Pharm GKB database, and excluded *loci* that could not be designed. We successfully genotyped 66 VIP variants selected from PharmGKB in 194 participants (98 Miao subjects and 96 Chinese Han controls). Genomic DNA was isolated from whole blood using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Ltd. Xi'an, China) according to the manufacturer's protocol. DNA concentration was measured by NanoDrop 2000C (Thermo Scientific, Waltham, Massachusetts, USA). We used the Sequenom MassARRAY Assay Design 3.0 software (San Diego, CA, USA) to design Multiplexed SNP MassEXTEND assays \[[@b10-medscimonit-21-3769]\]. Single-nucleotide polymorphism (SNP) genotyping used the standard protocol recommended by the manufacturer with a Sequenom MassARRAY RS1000 (San Diego, California, USA). Sequenom Typer 4.0 Software (San Diego, California, USA) was used to perform data management and analyze the SNP genotyping data, as described in a previous report \[[@b11-medscimonit-21-3769]\].

HapMap genotype data
--------------------

The genotype data of the 11 populations were downloaded from the International HapMap Project web site (HapMap_release127) at *<http://hapmap.ncbi.nlm.nih.gov>*. The 11 populations are as follows: (1) African ancestry in Southwest USA (ASW); (2) Utah, USA residents with Northern and Western European ancestry from the CEPH collection (CEU); (3) Han Chinese in Beijing, China (CHB); (4) Chinese in metropolitan Denver, CO, USA (CHD); (5) Gujarati Indians in Houston, Texas, USA (GIH); (6) Japanese in Tokyo, Japan (JPT); (7) Luhya in Webuye, Kenya (LWK); (8) Mexican ancestry in Los Angeles, California, USA (MEX); (9) Maasai in Kinyawa, Kenya (MKK); (10) Toscani in Italy (TSI); and (11) Yoruba in Ibadan, Nigeria (YRI).

Data analysis
-------------

We used Microsoft Excel (Redmond, WA, USA) and SPSS 17.0 statistical packages (SPSS, Chicago, IL, USA) to perform statistical calculations. The validity of the frequency of each VIP variant in the Miao and Chinese Han data was tested by assessing the departure from HWE using an exact test. We calculated and compared the genotype frequencies of the variants in the Miao data with those in the 11 populations separately using the χ^2^ test \[[@b12-medscimonit-21-3769]\]. All *p* values obtained in this study were 2-sided, and Bonferroni adjustment for multiple tests was applied to the level of significance, which was set at *p*\<0.05/(66\*12) \[[@b13-medscimonit-21-3769]\]. Structure (version 2.3.4) software \[[@b14-medscimonit-21-3769]\] was used to analysis the genetic structure of the 13 populations. We used Arlequin (version 3.1) software to calculate the value of Fst to infer the pairwise distance between populations \[[@b15-medscimonit-21-3769]\].

Results
=======

We successfully sequenced 66 VIP pharmacogenomic variant genotypes from 98 Miao individuals. The basic information about the selected VIP *loci* in Miao is listed in [Table 1](#t1-medscimonit-21-3769){ref-type="table"}, including gene name and category, chromosome number and position, amino acid translation, and their allele frequencies in Miao.

We used the χ^2^ test with the Bonferroni correction for multiple hypotheses and multiple comparisons, and we found 5, 7, 12, 13, 14, 15, 15, 16, 16, 19, 19, and 25 different *loci* in the frequency distributions when the Miao population was compared to the Xi'an Han, CHD, MEX, ASW, JPT, CHB, GIH, MKK, TSI, CEU, LWK, and YRI populations, respectively (*p*≤6.3×10^−5^). These VIP variants are mainly distributed in 23 genes; they mainly involve the cytochrome P450 superfamily, nuclear receptor family, G-protein-coupled receptor family, alcohol dehydrogenase family, adrenergic receptors family, ATP-binding cassette (ABC) transporters superfamily, and eag family. Genotype frequencies of *MTHFR, VDR,* and *VKORC1* in the Miao differed widely from those in the other 12 populations. We found that the rs1801133 was the most significantly different locus between the Miao ethnic group and the other populations ([Table 2](#t2-medscimonit-21-3769){ref-type="table"}). Additionally, Rs698, Rs1805124, and Rs 1801131 were found to show a significant difference in the 11 HapMap populations.

Pairwise Fst values were calculated for all population comparisons across *loci*. As shown in [Table 3](#t3-medscimonit-21-3769){ref-type="table"}, we found that pairwise Fst values for comparisons of the Miao population with the other 12 populations ranged from 0.01904 to 0.26192. Fst statistics \[[@b16-medscimonit-21-3769]\] are measures of population differentiation. It is directly related to the variance in allele frequency among populations and to the degree of resemblance among individuals within populations. If Fst is small, it means that the allele frequencies within each population are similar; if it is large, it means that the allele frequencies are different. The value of Fst for the Miao and CHD populations was the smallest. We therefore conclude that the allele frequencies of the Miao and CHD are similar. We speculate that the genetic backgrounds of the Miao and CHD populations are similar.

We used a model-based clustering approach, as implemented in Structure, to infer population structure among the 13 populations. Different values ranging from 2 to 7 were assumed for K in Structure calculations. K=3 was selected, based on the estimated Ln Prob of Data and other recommendations of the Structure software manual. As shown in [Figure 1](#f1-medscimonit-21-3769){ref-type="fig"}, when the K value was equal to 3, individuals were independently assigned to 3 affinity groups (subpopulations 1: Miao, Xi'an Han, CHB, CHD, JPT; subpopulations 2: ASW, LWK, MKK, YRI; subpopulations 3: CEU, GIH, MEX, TSI) using the relative majority of likelihood to assign individuals to subpopulations. We tested additional values of K and obtained results suggesting that the genetic backgrounds of the Miao and CHD populations are similar.

Discussion
==========

Individuals' differences in drug reactions can directly influence the efficacy and safety of the drug, and has become a worldwide problem in the treatment of some major diseases. However, it is almost impossible to predict whether a drug will be beneficial, lack efficacy, or cause serious adverse effects \[[@b17-medscimonit-21-3769]\]. Because genetic variations play an important role in determining the metabolism of and reactions to some specific drugs in individual patients, in this study we genotyped the variants related to drug response (pharmacogenomics) in the Miao ethnic group and compared the genotype frequencies with those in 12 other populations. The χ^2^ test results show that the allele frequencies of the *VDR* rs1544410 and *VKORC1* (rs9934438) variants in the Miao population are quite different from that in other ethnic groups. We found that genotype frequencies of rs1801133 (*MTHFR*) in the 13 selected populations are significantly different. Using Fst calculations and analysis of population structure, we also found that the genetic backgrounds of the Miao and CHD population are similar.

Methylenetetrahydrofolate reductase (MTHFR), located on chromosome 1 at 1p36.3, is an important enzyme involved in the folate metabolic pathway. Rs1801133 (677 C\>T) is a significant variant of the MTHFR gene. In our present study, rs1801133 was found to be a significant variant that existed in the 13 selected populations. It has been widely reported that the polymorphism of rs1801133 is associated with many diseases, such as breast cancer \[[@b18-medscimonit-21-3769]\], colorectal cancer \[[@b19-medscimonit-21-3769]\], and bladder cancer \[[@b20-medscimonit-21-3769]\]. A previous meta-analysis demonstrated that the 677 C allele was significantly associated with breast cancer risk (OR=0.942, 95%CI = 0.898 to 0.988) when compared with the 677 T allele in the additive model \[[@b18-medscimonit-21-3769]\]. In our study, the C allele frequency in Miao was somewhat high (28%) in our present study, suggesting that Miao have an intermediate susceptibility to breast cancer. Sohn et al. \[[@b21-medscimonit-21-3769]\] demonstrated that the MTHFR 677T mutation decreased chemosensitivity of breast cancer cells to methotrexate (MTX), a common cancer chemotherapeutic agent. Cáliz et al. \[[@b22-medscimonit-21-3769]\] also reported that the C677T polymorphism (rs1801133) was associated with increased MTX toxicity \[odds ratio (OR) 1.42, 95% confidence interval (CI) 1.01--1.98, p=0.0428\] in a Spanish rheumatoid arthritis population. These findings suggest that the MTHFR C677T polymorphism may be a useful pharmacogenetic determinant for providing rational and effectively tailored therapy for the Miao ethnic group.

Vitamin D receptor (VDR) gene maps to chromosome 12q13.11, whose function has been widely reported. It is an important regulator of the vitamin D pathway and a number of common single-nucleotide polymorphisms (SNP) have been identified in this gene \[[@b23-medscimonit-21-3769]\]. Clinical evidence suggests that the VDR genotype could modify the efficacy of anti-osteoporotic treatments such as etidronate and alendronate in postmenopausal women \[[@b24-medscimonit-21-3769]\]. Other studies have demonstrated that the SNP rs1544410 in VDR might modulate the risk of breast, skin, and prostate cancers, as well as other forms \[[@b25-medscimonit-21-3769],[@b26-medscimonit-21-3769]\]. One study reported that GA and AA genotypes of rs1544410 were associated with decreased cutaneous malignant melanoma (CMM) risk (odds ratio=0.78 and 0.75, respectively) compared with the GG genotype \[[@b26-medscimonit-21-3769]\]. We found that the GG genotype frequency of rs1544410 in the Miao is very high, suggesting that the Miao should consider more aggressive screening for CMM.

The VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene encodes the VKORC1 (vitamin K epoxide reductase) protein, which is considered a candidate gene for the variability in warfarin response, mainly including 3 common polymorphisms \[[@b27-medscimonit-21-3769]\]. The C6484T (rs9934438), or 1173C\>T (rs9934438), is a SNP in the first intron of VKORC1, which was the first SNP associated with the low-dose warfarin phenotype \[[@b28-medscimonit-21-3769]\]. A previous study demonstrated that patients with the 1173T (rs9934438) allele require a lower warfarin dose (mean dose 24--26 mg/week) compared with 35 mg/week for the wild-type carriers \[[@b29-medscimonit-21-3769]\]. In our study, the frequency of carriers of the allele T of rs9934438 is lower in the Miao population, suggesting that patients in this population will require a lower dose of warfarin.

Our study also demonstrated the correlation between the ethnic groups by Fst calculations and population structure analysis. The Structure plot ([Figure 1](#f1-medscimonit-21-3769){ref-type="fig"}) showed that the 13 ethnic groups were independently assigned into 3 affinity groups, suggesting they have a homogeneous genetic background. Genetic homogeneity among some populations separated by large geographic distances has been observed in migratory insects \[[@b30-medscimonit-21-3769],[@b31-medscimonit-21-3769]\]. Our results are consistent with those findings, which could be explained by the migration theory described by Curry et al. \[[@b32-medscimonit-21-3769]\].

Despite the current study possessing enough power, some limitations should be considered. First, the sample size of our study was relatively small, which may limit the statistical power. Second, the SNPs tested in our study were not large enough. Therefore, the association between these polymorphisms requires further investigation in a large sample before definitive conclusions can be drawn.

Conclusions
===========

Our results provide the first pharmacogenomics information in the Miao population and illustrate the difference in selected genes between Miao and 12 other populations around the world. These results could be used to create individualized treatment strategies, including appropriate drugs and dosage selections for the Miao ethnic group.
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###### 

Basic information about the selected variants and allele frequencies in the Miao ethnicity.

  SNP ID       Genes     Category                                    Amino acid translation   Chromosome   Position   Allele      Allele frequencies               
  ------------ --------- ------------------------------------------- ------------------------ ------------ ---------- ----------- -------------------- --- ------- -------
  rs1801131    MTHFR     Methylenetetrahydrofolate reductase         Phase I                  Glu429Ala    1          11854476    C                    A   1       0
  rs1801133    MTHFR     Methylenetetrahydrofolate reductase         Phase I                  Ala222Val    1          11856378    T                    C   0.72    0.28
  rs20417      PTGS2     Nuclear receptor                            Others                   --           1          186650320   G                    C   1       0
  rs689466     PTGS2     Nuclear receptor                            Others                   --           1          186650750   A                    G   0.49    0.51
  rs3918290    DPYD      --                                          Phase I                  --           1          97915614    G                    /   1       0
  rs6025       F5        --                                          Others                   Arg534Gln    1          169519049   C                    A   1       0
  rs890293     CYP2J2    Cytochrome P450                             Phase I                  --           1          60392494    G                    T   0.34    0.66
  rs4148323    UGT1A10   UDP--glucuronosyltransferase                Phase Ii                 Gly71Arg     2          234669144   A                    G   0.23    0.77
  rs1065776    P2RY1     G--protein coupled receptor                 Others                   Ala19Ala     3          152553628   T                    C   0.96    0.04
  rs2046934    P2RY12    G--protein coupled receptor                 Others                   --           3          151057642   T                    C   0.19    0.81
  rs3814055    NR1I2     Nuclear receptor                            Others                   --           3          119500034   C                    T   0.91    0.09
  rs1805124    SCN5A     Sodium channel gene                         Others                   Pro1090Leu   3          38645420    G                    A   0.85    0.15
  rs6791924    SCN5A     Sodium channel gene                         Others                   Arg34Cys     3          38674699    G                    /   1       0
  rs7626962    SCN5A     Sodium channel gene                         Others                   Ser1103Tyr   3          38620907    G                    /   1       0
  rs975833     ADH1A     Alcohol dehydrogenase                       Phase I                  --           4          100201739   G                    C   0.75    0.25
  rs1229984    ADH1B     Alcohol dehydrogenase                       Phase I                  His48Arg     4          100239319   G                    A   0.68    0.32
  rs2066702    ADH1B     Alcohol dehydrogenase                       Phase I                  Arg370Cys    4          100229017   C                    T   1       0
  rs698        ADH1C     Alcohol dehydrogenase                       Phase I                  Ile350Val    4          100260789   A                    G   0.95    0.05
  rs1042713    ADRB2     Adrenergic receptors                        Others                   Ala222Val    5          148206440   G                    A   0.48    0.52
  rs1042714    ADRB2     Adrenergic receptors                        Others                   --           5          148206473   G                    C   0.98    0.02
  rs1800888    ADRB2     Adrenergic receptors                        Others                   Thr164Ile    5          148206885   C                    T   1       0
  rs17238540   HMGCR     --                                          Phase I                  --           5          74619742    T                    /   1       0
  rs17244841   HMGCR     --                                          Phase I                  --           5          74607099    A                    /   0.99    0.01
  rs3846662    HMGCR     --                                          Phase I                  --           5          74615328    T                    C   0.57    0.43
  rs1142345    TPMT      Methyltransferase superfamily               Phase Ii                 Tyr240Cys    6          18130918    G                    A   0.99    0.01
  rs1045642    ABCB1     ABC transporters                            Others                   Ile1145Ile   7          87138645    T                    C   0.65    0.35
  rs1128503    ABCB1     ABC transporters                            Others                   Gly412Gly    7          87179601    T                    C   0.33    0.67
  rs2066853    AHR       AHR                                         Others                   Arg554Lys    7          17379110    G                    A   0.52    0.48
  rs12720441   KCNH2     Eag                                         Others                   Arg444Trp    7          150647304   C                    /   1       0
  rs36210421   KCNH2     Eag                                         Others                   Arg707Leu    7          150644428   G                    T   1       0
  rs3807375    KCNH2     Eag                                         Others                   --           7          150667210   A                    G   0.78    0.22
  rs3815459    KCNH2     Eag                                         Others                   --           7          150644394   A                    G   0.73    0.27
  rs2740574    CYP3A4    Cytochrome P450                             Phase I                  --           7          99382096    A                    G   0.99    0.01
  rs12721634   CYP3A4    Cytochrome P450                             Phase I                  Leu15Pro     7          99381661    T                    /   1       0
  rs4986909    CYP3A4    Cytochrome P450                             Phase I                  Pro416Leu    7          99359670    C                    /   0.74    0.26
  rs4986910    CYP3A4    Cytochrome P450                             Phase I                  Met445Thr    7          99358524    T                    /   1       0
  rs10264272   CYP3A5    Cytochrome P450                             Phase I                  Lys208Lys    7          99262835    C                    /   1       0
  rs1801252    ADRB1     Adrenergic receptors                        Others                   Ser49Gly     10         115804036   G                    A   0.66    0.34
  rs1799853    CYP2C9    Cytochrome P450                             Phase I                  Arg144Cys    10         96702047    C                    T   1       0
  rs4244285    CYP2C19   Cytochrome P450                             Phase I                  Pro227Pro    10         96541616    G                    A   0.32    0.68
  rs4986893    CYP2C19   Cytochrome P450                             Phase I                  Trp212null   10         96540410    G                    /   0.015   0.985
  rs1138272    GSTP1     Glutathione S--transferase                  Phase Ii                 Ala114Val    11         67353579    T                    C   1       0
  rs1695       GSTP1     Glutathione S--transferase                  Phase Ii                 Ile105Val    11         67352689    A                    G   0.889   0.121
  rs1800497    DRD2      G-protein-coupled receptor                  Others                   Glu713Lys    11         113270828   T                    C   0.59    0.41
  rs6277       DRD2      G-rotein-coupled receptor                   Others                   Pro290Pro    11         113283459   G                    A   0.985   0.015
  rs5219       KCNJ11    Inward-rectifier potassium channel family   Others                   Lys23Glu     11         17409572    C                    T   0.939   0.061
  rs11568820   VDR       Nuclear receptor                            Others                   --           12         48302545    G                    A   0.54    0.46
  rs1540339    VDR       Nuclear receptor                            Others                   --           12         48257326    G                    A   0.78    0.22
  rs1544410    VDR       Nuclear receptor                            Others                   --           12         48239835    G                    A   0.99    0.01
  rs2239185    VDR       Nuclear receptor                            Others                   --           12         48244559    T                    C   0.78    0.22
  rs9934438    VKORC1    VKORC1                                      Phase I                  --           16         31104878    G                    A   0.87    0.13
  rs1801030    SULT1A1   Sulfotransferase                            Phase Ii                 Val223Met    16         28617485    A                    /   1       0
  rs3760091    SULT1A1   Sulfotransferase                            Phase Ii                 --           16         28620800    C                    G   0.74    0.26
  rs1801272    CYP2A6    Cytochrome P450                             Phase I                  Leu160His    19         41354533    T                    /   1       0
  rs28399433   CYP2A6    Cytochrome P450                             Phase I                  --           19         41356379    G                    T   0.23    0.77
  rs28399444   CYP2A6    Cytochrome P450                             Phase I                  Glu197Arg    19         41354190    A                    /   1       0
  rs28399454   CYP2A6    Cytochrome P450                             Phase I                  Val365Met    19         41351267    G                    /   1       0
  rs28399499   CYP2B6    Cytochrome P450                             Phase I                  Ile328Thr    19         41518221    T                    /   1       0
  rs3211371    CYP2B6    Cytochrome P450                             Phase I                  Arg487Cys    19         41522715    C                    T   0.50    0.50
  rs1051266    SLC19A1   Solute carrier                              Others                   His27Arg     21         46957794    G                    A   0.57    0.43
  rs4680       COMT      COMT                                        Phase Ii                 Val158Met    22         19951271    A                    G   0.79    0.21
  rs16947      CYP2D6    Cytochrome P450                             Phase I                  --           22         42523943    G                    A   0.05    0.95
  rs28371706   CYP2D6    Cytochrome P450                             Phase I                  Thr107Ile    22         42525772    C                    T   0.995   0.005
  rs28371725   CYP2D6    Cytochrome P450                             Phase I                  --           22         42523805    G                    A   0.05    0.95
  rs5030656    CYP2D6    Cytochrome P450                             Phase I                  --           22         42524175    AAG                  /   0.50    0.50
  rs61736512   CYP2D6    Cytochrome P450                             Phase I                  Val136Met    22         42525134    C                    /   1       0

###### 

Significant variants in Miao compared to the twelve populations determined by Chi-square test.

  SNP          Genes     Chi-square test p-value (after Bonferroni correction)                                                                                                                 
  ------------ --------- ------------------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  rs1042713    ADRB2     --                                                      1.08E-05   --         3.37E-06   5.00E-07   --         --         --         1.35E-06   --         4.63E-05   4.83E-05
  rs1042714    ADRB2     --                                                      --         4.62E-18   7.97E-29   --         --         2.67E-28   --         --         --         1.92E-29   --
  rs1045642    ABCB1     --                                                      --         1.02E-10   --         --         2.39E-05   --         --         8.43E-06   --         1.21E-07   --
  rs1051266    SLC19A1   --                                                      --         3.05E-08   --         --         --         --         --         9.94E-12   --         2.11E-06   4.12E-08
  rs1128503    ABCB1     --                                                      6.40E-14   5.21E-07   --         --         --         --         --         3.60E-25   8.25E-06   1.01E-24   4.72E-23
  rs1142345    TPMT      --                                                      1.17E-32   --         --         --         --         --         --         --         --         --         8.35E-39
  rs11568820   VDR       --                                                      --         --         --         --         --         --         1.34E-07   9.98E-07   1.01E-07   1.52E-22   9.39E-11
  rs1229984    ADH1B     --                                                      --         --         1.35E-11   --         --         2.86E-10   --         --         --         --         --
  rs1540339    VDR       --                                                      1.15E-14   3.35E-13   --         --         4.27E-13   --         9.34E-09   1.64E-27   5.39E-13   3.91E-23   1.05E-24
  rs1544410    VDR       3.80E-41                                                9.22E-32   1.44E-27   --         --         1.81E-29   4.34E-39   3.38E-29   2.03E-35   6.31E-28   2.01E-38   9.08E-36
  rs1695       GSTP1     --                                                      8.63E-09   --         --         --         2.39E-06   --         4.02E-10   6.13E-08   1.65E-05   5.05E-09   1.46E-14
  rs1800497    DRD2      --                                                      --         --         --         --         4.40E-10   --         --         6.38E-07   2.20E-13   --         1.32E-05
  rs1801131    MTHFR     --                                                      1.03E-15   3.89E-14   4.97E-18   6.97E-18   1.10E-09   5.32E-20   2.44E-14   1.50E-19   1.10E-12   1.35E-27   2.35E-20
  rs1801133    MTHFR     2.75E-07                                                5.58E-20   9.97E-14   2.44E-05   7.81E-11   4.04E-20   2.99E-10   5.34E-06   2.44E-33   5.93E-06   9.64E-29   5.70E-26
  rs1805124    SCN5A     --                                                      1.03E-17   8.80E-28   6.45E-29   2.36E-30   9.16E-26   3.79E-28   3.71E-21   3.48E-22   4.53E-23   2.71E-24   2.47E-21
  rs20417      PTGS2     --                                                      --         6.78E-32   --         --         --         --         --         --         --         2.03E-26   --
  rs2046934    P2RY12    --                                                      --         6.28E-17   1.85E-18   --         --         6.41E-19   --         --         --         1.95E-20   --
  rs2066702    ADH1B     --                                                      2.52E-30   --         --         --         --         --         --         1.26E-52   --         2.09E-40   4.88E-40
  rs2066853    AHR       --                                                      --         6.29E-08   --         --         6.25E-13   --         1.60E-08   --         2.07E-14   --         --
  rs2239185    VDR       --                                                      --         --         8.08E-11   --         --         8.76E-06   --         --         --         --         --
  rs28399454   CYP2A6    --                                                      1.62E-33   --         --         --         --         --         --         --         --         4.13E-46   6.73E-41
  rs28399499   CYP2B6    --                                                      --         --         --         --         --         --         --         --         --         7.82E-45   1.50E-41
  rs3760091    SULT1A1   5.37E-05                                                --         --         --         ----       --         --         --         --         --         --         --
  rs3807375    KCNH2     --                                                      --         3.73E-16   --         --         1.30E-12   --         --         --         2.73E-14   --         --
  rs3814055    NR1I2     --                                                      --         3.96E-08   --         --         7.55E-12   --         --         --         5.27E-10   1.15E-05   1.18E-05
  rs3815459    KCNH2     --                                                      --         --         --         --         --         --         --         --         --         1.15E-08   --
  rs3846662    HMGCR     --                                                      1.11E-06   --         --         --         --         --         --         1.12E-09   --         4.95E-18   1.36E-16
  rs4148323    UGT2A     --                                                      --         --         1.54E-19   3.11E-20   1.09E-31   4.60E-23   4.52E-23   --         --         1.58E-28   --
  rs4244285    CYP2C19   --                                                      --         9.13E-07   5.07E-10   --         --         1.17E-08   --         --         --         8.56E-17   --
  rs4680       COMT      9.20E-21                                                --         8.99E-07   --         --         3.32E-06   --         --         --         2.48E-07   --         --
  rs4986909    CYP3A4    --                                                      --         --         9.66E-39   --         --         3.55E-39   2.29E-30   --         --         2.20E-34   --
  rs5219       KCNJ11    2.06E-05                                                --         --         --         --         --         --         --         --         --         --         --
  rs6277       DRD2      --                                                      --         4.12E-21   6.85E-30   --         --         --         --         --         --         --         --
  rs689466     PTGS2     --                                                      1.12E-09   --         --         --         2.92E-10   --         --         1.22E-26   6.81E-09   4.29E-16   1.69E-19
  rs698        ADH1C     --                                                      2.70E-23   1.14E-21   5.18E-34   1.07E-33   1.93E-28   1.37E-33   5.20E-23   6.93E-38   2.40E-25   1.32E-39   1.45E-31
  rs975833     ADH1A     --                                                      --         --         2.11E-15   --         --         1.00E-13   --         --         --         --         --
  rs9934438    VKORC1    --                                                      --         1.17E-07   9.85E-34   6.97E-33   --         2.70E-31   1.81E-08   --         2.42E-11   --         --

###### 

Pairwise Fst values between populations.

  Population      Miao      Xi'an Han   ASW       CEU       CHB       CHD       GIH       JPT       LWK       MEX       MKK       TST       YRI
  --------------- --------- ----------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  **Miao**        0.00000                                                                                                                   
  **Xi'an Han**   0.03382   0.00000                                                                                                         
  **ASW**         0.20416   0.20827     0.00000                                                                                             
  **CEU**         0.1826    0.15671     0.13819   0.00000                                                                                   
  **CHB**         0.02257   0.00211     0.20498   0.15471   0.00000                                                                         
  **CHD**         0.01904   0.00747     0.19789   0.14808   −0.0012   0.00000                                                               
  **GIH**         0.18045   0.17073     0.08734   0.02836   0.15889   0.15163   0.00000                                                     
  **JPT**         0.02566   0.01533     0.18516   0.14938   0.00547   0.00582   0.15292   0.00000                                           
  **LWK**         0.25869   0.27541     0.01665   0.20017   0.26908   0.26468   0.14679   0.24248   0.00000                                 
  **MEX**         0.13783   0.09328     0.11843   0.02856   0.10109   0.09437   0.05388   0.10439   0.1902    0.00000                       
  **MKK**         0.22133   0.23686     0.01934   0.14697   0.22869   0.22481   0.10441   0.19944   0.0145    0.1537    0.00000             
  **TSI**         0.16704   0.13282     0.13316   0.0034    0.12909   0.1282    0.03023   0.12535   0.19757   0.02613   0.14577   0.00000   
  **YRI**         0.26192   0.28092     0.01823   0.21784   0.27486   0.27251   0.15499   0.24575   0.00361   0.20902   0.01936   0.21334   0.00000

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection

[^8]: Tian bo Jin and Ainiwaer Aikemu are joint first authors
